We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips
Read MoreHide Full Article
Cardiovascular Systems, Inc. has been pursuing product improvements, as well as evaluating new technologies in a bid to strengthen and broaden its portfolio of powerful micro-invasive tools. The stock currently carries a Zacks Rank #3 (Hold).
Coronary franchise registered solid performance on a strong procedure volume domestically, increased sales of procedure support products, and growing adoption of orbital atherectomy internationally.
The company’s third-quarter fiscal 2021 international revenues increased 20.5% year over year led by strong growth in Japan banking on successful Orbital Atherectomy System (OAS) launches three years back. Cardiovascular Systems received the CE Mark for coronary OAS in January and is employing the same launch approach in Europe. Despite the pandemic, the company launched coronary system in six European countries in less than two months.
The company is progressing well with its objective to introduce OAS globally. In this regard, Cardiovascular Systems is progressing well under its partnership with OrbusNeich per which the latter distributes the company’s coronary and peripheral orbital atherectomy systems in multiple countries outside the United States and Japan.
The company is currently working with regulatory authorities regarding the launch of the WIRION Embolic Protection System and will begin offering peripheral support devices in the fourth quarter of fiscal 2021.
On the flip side, the company’s third-quarter fiscal 2021 loss was wider than the year-ago figure as well as the consensus mark. Revenues missed the Zacks Consensus Estimate but improved on a year-over-year basis.
Peripheral revenues were flat as patients with claudication continued to defer evaluation and treatment. Peripheral units sold to hospitals declined 6% due to ongoing deferral of treatment for claudication. Gross margin contraction was deterring as well. Continued net operating loss does not bode well for the company. A tough competitive landscape and the company’s failure to expand business overseas are other headwinds.
Over the past three months, Cardiovascular Systems has underperformed the industry. The stock has lost 9.1% compared with the industry’s 2.5% fall.
National Vision has a projected long-term earnings growth rate of 23%.
Boston Scientific has a projected long-term earnings growth rate of 9%.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips
Cardiovascular Systems, Inc. has been pursuing product improvements, as well as evaluating new technologies in a bid to strengthen and broaden its portfolio of powerful micro-invasive tools. The stock currently carries a Zacks Rank #3 (Hold).
Coronary franchise registered solid performance on a strong procedure volume domestically, increased sales of procedure support products, and growing adoption of orbital atherectomy internationally.
The company’s third-quarter fiscal 2021 international revenues increased 20.5% year over year led by strong growth in Japan banking on successful Orbital Atherectomy System (OAS) launches three years back. Cardiovascular Systems received the CE Mark for coronary OAS in January and is employing the same launch approach in Europe. Despite the pandemic, the company launched coronary system in six European countries in less than two months.
Cardiovascular Systems, Inc. Price
Cardiovascular Systems, Inc. price | Cardiovascular Systems, Inc. Quote
The company is progressing well with its objective to introduce OAS globally. In this regard, Cardiovascular Systems is progressing well under its partnership with OrbusNeich per which the latter distributes the company’s coronary and peripheral orbital atherectomy systems in multiple countries outside the United States and Japan.
The company is currently working with regulatory authorities regarding the launch of the WIRION Embolic Protection System and will begin offering peripheral support devices in the fourth quarter of fiscal 2021.
On the flip side, the company’s third-quarter fiscal 2021 loss was wider than the year-ago figure as well as the consensus mark. Revenues missed the Zacks Consensus Estimate but improved on a year-over-year basis.
Peripheral revenues were flat as patients with claudication continued to defer evaluation and treatment. Peripheral units sold to hospitals declined 6% due to ongoing deferral of treatment for claudication. Gross margin contraction was deterring as well. Continued net operating loss does not bode well for the company. A tough competitive landscape and the company’s failure to expand business overseas are other headwinds.
Over the past three months, Cardiovascular Systems has underperformed the industry. The stock has lost 9.1% compared with the industry’s 2.5% fall.
Stocks Worth a Look
A few better-ranked stocks from the broader medical space are National Vision Holdings, Inc. (EYE - Free Report) , Boston Scientific Corporation (BSX - Free Report) and Envista Holdings Corporation (NVST - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
National Vision has a projected long-term earnings growth rate of 23%.
Boston Scientific has a projected long-term earnings growth rate of 9%.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>